


# Applying Innovative Technology to Develop AlloCAR T™ Therapy



The process for manufacturing our off-the-shelf allogeneic CAR T cell (AlloCART™) therapy first involves harvesting healthy, selected, screened and tested T cells from healthy donors. This means that a larger portion of eligible patients, including those who are critically ill and have T cells that are difficult to harvest or expand, can potentially receive treatment, and no eligible patient will have to undergo leukapheresis (a laboratory procedure in which a patient’s white blood cells are separated and the remaining blood cells and plasma are returned to the patient).

Next, the T cells are engineered to express CARs, which recognize certain cell surface proteins that are expressed in hematologic or solid tumors. ALLO-501 and ALLO-501A, two of our investigational therapies, target CD19, while a third,

ALLO-715, targets BCMA, cell surface proteins expressed on B-cells, including cancerous B-cells. These are just the first candidates in a line of AlloCAR T™ therapies we plan to develop. The next step in the process involves gene editing to reduce the risk of graft versus host disease (GvHD) and allogeneic rejection. A T cell receptor gene is knocked out with the goal of avoiding GvHD. Knocking out the CD52 gene is expected to render the CAR T product resistant to anti-CD52 antibody treatment. ALLO-647, our proprietary anti-CD52 monoclonal antibody, should therefore be able to suppress the host immune system and potentially allow the AlloCAR T™ to stay engrafted to enhance therapeutic impact.

The engineered T cells then undergo a purification step and are ultimately cryopreserved in vials for delivery to patients.

## State-of-the-Art, In-House Manufacturing for Long-Term Clinical and Commercial AlloCAR T™ Production

Building world-class manufacturing capabilities is at the core of our strategy to deliver readily available AlloCARs™ faster, more reliably and at greater scale.

A new manufacturing facility, located in Newark, CA, in San Francisco’s East Bay Area, is being designed to provide GMP manufacturing for clinical supply and commercial

product upon potential regulatory approval, and will complement Allogene’s buildout of in-house process development and characterization capabilities.

Allogene currently manufactures its clinical trial supply through a contract manufacturing organization, which remains a component of our long-term manufacturing strategy.

To the extent statements contained in this fact sheet are not descriptions of historical facts regarding Allogene Therapeutics, Inc. (“Allogene,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This fact sheet shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

